Abbott Laboratories ABT recently announced the FDA clearance of a standalone reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system (iCGM). Through the reader, diabetes ...
Medical device giant Abbott announced on Sunday that it is recalling approximately 3 million glucose monitoring sensors after discovering they could give dangerously inaccurate low blood sugar ...
Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. The FDA cleared the FreeStyle Libre 3 ...
Fresh off receiving a long-awaited FDA clearance for its FreeStyle Libre 3 system, Abbott has racked up yet another major win for the continuous glucose monitor. Clinical results presented at the ...
This morning Abbott announced that its continuous glucose monitor the FreeStyle Libre 3 earned a CE mark, making it cleared for use for individuals with diabetes living in the European Union. This ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories has an early lead in painless diabetes ...
ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...
Please provide your email address to receive an email when new articles are posted on . A voluntary medical device correction warned users of three Abbott FreeStyle Libre readers about the risk of ...
Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...
ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the ...
How Much Can Abbott's Price Gain If FreeStyle Libre Gets 30% of The Blood Glucose Monitoring Market?
Abbott Labs’ (NYSE:ABT) stock price could gain over 10% if its FreeStyle Libre system captures a 30% share of the blood glucose monitoring market by 2020, according to our estimates. FreeStyle Libre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results